DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Saquinavir (Drug); Zidovudine (Drug); Zalcitabine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Hoffmann-La Roche

Official(s) and/or principal investigator(s):
Collier AC, Study Chair
Corey L, Study Chair

Summary

PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.

Clinical Details

Official title: Double-Blind, Randomized, Phase II Study of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Ro 31-8959 Plus AZT Plus ddC

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 13 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Prior Medication: Required:

- At least 4 months total of AZT at some point in the past, alone or in combination

with other antiretroviral therapy. Patients must have:

- HIV seropositivity.

- Diagnosis of AIDS, ARC, PGL, or asymptomatic infection.

- CD4 count > 50 to <= 300 cells/mm3.

- Life expectancy of at least 6 months.

- Prior AZT therapy.

Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded:

- Acute serious opportunistic infections requiring immediate treatment, including (but

not limited to) tuberculosis, CMV, cryptococcal meningitis, disseminated MAC, cerebral toxoplasmosis, and Pneumocystis carinii pneumonia.

- Known intolerance to Ro 31-8959, AZT, or ddC.

- Symptoms suggestive of pancreatitis.

- Moderate or severe peripheral neuropathy as evidenced by discomfort from numbness,

tingling, burning or pain of the extremities or any related symptoms that are accompanied by an objective finding.

- Visceral Kaposi's sarcoma.

- Lymphoma that will require therapy within the next 6 months.

- Transfusion dependence.

Concurrent Medication: Excluded:

- Investigational or antineoplastic agents.

Concurrent Treatment: Excluded:

- Radiotherapy (other than local skin radiotherapy).

- Transfusions.

Prior Medication: Excluded:

- Any antiretroviral agent (other than AZT) or immunomodulatory therapy within 14 days

prior to study entry.

- Prior treatment with an HIV proteinase inhibitor.

Locations and Contacts

Univ of Alabama at Birmingham, Birmingham, Alabama 35294, United States

Stanford Univ Med Ctr, Stanford, California 943055107, United States

Univ of Colorado Health Sciences Ctr, Denver, Colorado 80262, United States

Northwestern Univ Med School, Chicago, Illinois 60611, United States

Bellevue Hosp / New York Univ Med Ctr, New York, New York 10016, United States

Univ of Rochester Med Ctr, Rochester, New York 14642, United States

Ohio State Univ Hosp, Columbus, Ohio 432101228, United States

Girard Med Ctr, Philadelphia, Pennsylvania 191046073, United States

Univ TX Galveston Med Branch, Galveston, Texas 775550882, United States

Univ of Washington, Seattle, Washington 98122, United States

Additional Information

Click here for more information about Zidovudine

Click here for more information about Saquinavir

Related publications:

Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis. 1999 Jan;179(1):249-53.

Brambilla D, Coombs R, Bremer JW, Reichelderfer PS, Kalish L, Shapiro DE. The contributions of assay variation and biological variation to the variability of HIV RNA measurements in serially collected clinical specimens. Int Conf AIDS. 1998;12:805 (abstract no 42163)

Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, Corey L. Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res. 1996 Jan;29(1):99.

Collier AC, Coombs RW, Timpone J, Schoenfeld DA, Bassett R, Baruch A, Corey L. Comparative study of Ro 31-8959 and zidovudine (ZDV) vs. ZDV and zalcitabine (ddC) vs. Ro 31-8959, ZDV, and ddC. The ACTG 229 Protocol Team. Int Conf AIDS. 1994 Aug 7-12;10(1):21 (abstract no 058B)

Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 1996 Jul;52(1):93-112. Review.

Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov;41(11):2433-8.

Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996 Apr 18;334(16):1011-7.

Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med. 1995 Jan 1;122(1):24-32.

Schapiro JM, Lawrence J, Speck R, Winters MA, Coombs R, Collier AC, Efron B, Merigan TC. HIV RNA and resistance mutations to saquinavir and zidovudine in patients receiving dual versus triple combination therapy. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:154 (abstract no 401)


Last updated: February 28, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017